申请人:CELLIX BIO PRIVATE LIMITED
公开号:US11078154B2
公开(公告)日:2021-08-03
The disclosures herein provide compounds of formula I
or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.
本文公开的化合物为式 I
或其药用盐,以及它们的多晶型物、对映体、立体异构体、溶解物和水合物。这些盐类可配制成药物组合物。这些药物组合物可配制成口服、栓剂、透皮、口腔、直肠、局部、透皮、透粘膜、静脉注射、肠外给药、糖浆或注射剂。此类组合物可用于治疗肠易激综合征(IBS)、炎症性肠病或其相关并发症。